CD8A and leukemia: Immune monitoring (including standard immune status and leukemia-specific cell monitoring by ELISPOT and InCyt + LAA stimulation) at defined timepoints showed (other than before treatment and in the patient without Kit M treatment) a slight increase in DCs, proliferating T cells, and stable Tnon-naive of the CD8 and CD4 lines during Kit M treatment.